Articles tagged with Mesenchymal Stem Cells
Researchers have discovered that non-adherent bone marrow stem cells can differentiate into neuronal-like cells in vitro and in vivo. These findings suggest that non-adherent BMSCs could be used as seed cells to treat nervous system diseases.
A new recombinant antibody can detect and isolate mesenchymal stem cells (MSCs) from umbilical cord blood, a nonembryonic source with promising applications in tissue engineering and blood stem cell transplantation. The antibody recognizes an i blood group antigen present on MSCs.
A study published in Restorative Neurology and Neuroscience demonstrates that intracerebral injection of bone-marrow-derived mesenchymal stem cells reduces cognitive deficits produced by temporary occlusion of cerebral blood vessels in a rat model of stroke.
Researchers have successfully induced differentiation of Wharton's jelly mesenchymal stem cells into retinal progenitor cells, offering a promising new treatment option for visual impairment in retinal degenerative diseases. The study demonstrates the potential of these stem cells as seed cells for clinical treatment.
A new study by the Ostrow School of Dentistry of USC found that stem cells in gum tissue can relieve inflammatory diseases, including colitis. The cells, called gingival mesenchymal stem cells (GMSC), have the ability to become other cell types and affect the immune system.
Stem cells found in urine have been shown to differentiate into various cell types, including bladder, bone, cartilage, and endothelial cells. These cells offer a promising alternative for autologous therapy, potentially treating urology-related conditions and other fields.
Researchers found that melatonin pre-treatment increased cell survival of mesenchymal stem cells (MSCs) after transplantation into laboratory animals with stroke damage. The pre-treated MSCs showed enhanced survival under oxidative stimulation, reducing infarct volume and improving neurobehavioral outcomes.
Gingival stem cells derived from cranial neural crest cells and mesoderm show distinct capacities for differentiation and immune modulation. These cells demonstrate superior effects in ameliorating inflammatory-related disease phenotypes when transplanted into mice.
Scientists at Emory Health Sciences have developed a method to steer mesenchymal stem cells using magnets, which could potentially be used to treat cardiovascular diseases. The nanoparticles used in this study are FDA-approved for MRI purposes and protect the cell from damage.
A new technique developed by Stanford researchers allows for the tracking of mesenchymal stem cells after transplantation, giving surgeons a better sense of whether the procedure was successful. The approach uses an FDA-approved iron supplement to label the cells, alleviating risks associated with standard labeling methods.
Scientists have identified four pathways involved in the formation of myofibroblasts that drive destructive runaway scarring in organs. These pathways provide leads for drug targets to control fibrosis.
A recent study from the University of Pennsylvania has made a significant breakthrough in developing new therapies to replace cartilage tissue. Researchers have found that mimicking cadherin interactions can trick adult stem cells into producing better cartilage, offering a promising alternative to current surgical options.
Researchers at the University of Pennsylvania have found that a stem cell's environment influences its differentiation into various cell types, with 'grip' playing a crucial role. The study suggests that three-dimensional matrices impact mechanotransduction, guiding stem cell fate and differentiation.
Researchers at IDIBELL and VHIR have developed a treatment using adult mesenchymal stem cells to regenerate damaged lung tissue and reduce inflammation. The licensed product has shown promising results in animal models of acute respiratory distress and allergic asthma.
Researchers create a new imaging technique using nanoparticles to track stem cells in real-time, allowing for better initial placement and optimization of therapeutic approaches. The technique enables precise guidance and monitoring of stem cells, potentially improving regenerative medicine treatments.
Researchers found that allogeneic hematopoietic stem cell transplantation with mesenchymal stem cells from third-party donors improved poor graft function in five patients with acute GVHD and two with chronic GVHD. The treatment also showed promise in reducing morbidity and mortality.
Researchers found that nano-hMSCs can promote cavernous neuronal regeneration and repair erectile dysfunction. The study revealed that transplantation of nano-hMSCs increased the expression levels of cavernous neuronal, endothelial, and smooth muscle makers.
Researchers at King's College London have developed a new method for replacing missing teeth with bioengineered material from human gum cells. The technique, which uses adult human epithelial cells and mouse mesenchyme cells, can produce functional teeth with viable roots and dentine.
Scientists at Stanford University School of Medicine have discovered that tuberculosis bacteria can infiltrate and settle in mesenchymal stem cells in the bone marrow. This finding raises the possibility that other infectious agents may employ similar tactics, providing a new potential target for treatment. The research suggests that u...
Researchers have developed a method to expand umbilical cord blood cells on mesenchymal precursor cells, speeding up the establishment of a new blood supply in patients. This approach has shown faster engraftment of white blood cells and platelets, resulting in improved patient outcomes.
Researchers developed a new method to create long-lived stem cells for bone replacement by inserting human telomerase into mesenchymal stem cells. This allows the stem cells to retain their ability to become bone cells and divide repeatedly, making them suitable for tissue engineering applications.
Researchers at the University of Toronto have found that Human Umbilical Cord PeriVascular Cells (HUCPVCs) are more effective than bone marrow cells in restoring heart function after a heart attack. The study demonstrates that HUCPVC cell therapy is twice as effective at repairing damage to heart tissue than no treatment.
Researchers investigated the use of stem cells in treating equine tendon injuries. Bone marrow-derived mesenchymal stem cells and adipose-derived stem cells showed promise in strengthening tendons after injury, while umbilical cord blood-derived stem cells may offer even greater potential for tendon regeneration.
Researchers used magnetic particles to target transplanted stem cells to specific retinal locations, improving biochemical changes in the target tissue. Magnetic targeting also enhanced cell retention in a rat model of ischemia/reperfusion injury by over five-fold.
Researchers found that mesenchymal stem cell transplantation in animal models of amyotrophic lateral sclerosis (ALS) and spinal cord injury promotes functional recovery. Bone marrow cell transplantation coupled with granulocyte colony-stimulating factor also shows neuroprotective and angiogenic effects in ALS animal models.
Researchers have discovered that cells from burn eschar can differentiate into multipotent mesenchymal stromal cells, which could be used to treat burn injuries. The study found that these cells had a resemblance to adipose-derived stem cells and may play a crucial role in wound healing.
Researchers have identified three types of fetal cells in maternal organs: trophoblasts, mesenchymal stem cells, and immune system cells. These cells may help the mother's immune system tolerate the fetus and aid in organ repair.
Researchers have found that the omentum's fat cells can suppress the immune system by sequestering activated T cells, a finding that could lead to new drugs with fewer side effects. The omentum also helps regenerate damaged tissues through mesenchymal stem cells.
A substance in human mesenchymal stem cells promotes nerve restoration and myelin sheath repair in rodent models of multiple sclerosis. Hepatocyte growth factor, a key instigator, decreases inflammation and increases signaling molecules counteracting it, leading to neural cell growth and nerve rewinding.
A new study reveals that mesenchymal stem cell infusions can control autoimmune disorders by targeting and defeating overactive immune cells through the FAS/FAS-ligand pathway, showing promising results in both animal models and human patients.
A study published in Cell Transplantation found that human umbilical cord-derived mesenchymal cells effectively reduced clinical and pathological severity of induced colitis in test mice. The treatment inhibited pro-inflammatory cytokine expression, indicating its potential for treating inflammatory bowel diseases.
Researchers at MIT have developed a new coating for hip implants that promotes bone growth, creating a stronger seal between the implant and the patient's own bone. This coating could prevent premature failure and reduce the risk of infection, allowing patients to walk and perform physical therapy during the healing process.
Using bone marrow-derived mesenchymal stem cells instead of antibody induction therapy reduces acute rejection, opportunistic infections, and improves estimated kidney function at 1 year. Autologous MSC infusion is a promising alternative to traditional immunosuppressive protocols.
Researchers report successful early transplantation of human placenta-derived mesenchymal stem cells into neonatal rats with birth-related brain damage, detecting neurologic improvement.
Researchers at the University of Michigan Comprehensive Cancer Center have found that mesenchymal stem cells, normally used for wound healing, are recruited by cancer stem cells to fuel ovarian cancer growth. By blocking this process with a protein called BMP2, researchers may have discovered a potential therapy for ovarian cancer.
Researchers at Case Western Reserve University found that mesenchymal stem cells can inhibit an overactive immune system and promote tissue repair. These cells have shown potential in treating conditions such as acute heart attack, stroke, kidney failure, and juvenile diabetes.
Researchers identify VIP signaling pathway key for normal brain development, finding that environmental factors can influence final brain size. A new approach to treating Parkinson's disease is also suggested with T-type calcium channel blockade.
Researchers at Mount Sinai School of Medicine discovered a cellular signaling pathway governing fat tissue and vascular smooth muscle differentiation. Elevated PDGFRβ signaling inhibits the formation of fat cells, offering new therapeutic targets for preventing obesity and cardiovascular disease.
Breast cancer stem cells can be induced to transition into a mesenchymal and stem cell-like state by signals from breast epithelial cells. Blocking these autocrine signals inhibits the growth of tumors in animal models. The study suggests that targeting these signals could lead to effective treatment for breast cancer.
Aging stem cells struggle to produce strong bones due to malnutrition and inadequate signals. Researchers explore the role of amino acids and satiety hormone leptin in rejuvenating these cells.
Researchers at Salk Institute successfully edit a diseased gene in patient-specific induced pluripotent stem cells and adult stem cells using a virus-based approach. The method provides an efficient and safe tool for cell engineering, opening the way for gene editing-based stem cell therapies suitable for clinical applications.
Researchers grew mesenchymal stem cells as tiny spheres to form a variety of cell types, expanding their potential for regenerative medicine. The 3D technique recreates the microscopic environment found in human bodies, allowing MSCs to specialize more rapidly and completely.
A newly discovered activity of the p53 gene activates microRNA miR-200c to reverse epithelial-to-mesenchymal transition in breast cancer cells. The study offers a potential therapeutic strategy for targeting tumor-initiating cells with stem cell characteristics.
Researchers at BWH have engineered human mesenchymal adult stem cells with internal depots that can slowly release agents to influence cell behavior. The cells demonstrated controlled differentiation into bone cells, even affecting distant cells.
Scientists have created the world's first human cell model of progeria, a rare genetic disease causing severe premature ageing in children. The model reveals defects in mesenchymal stem cells and vascular smooth muscle cells that exacerbate symptoms of ageing.
A protein called CDK1 deactivates the cancer-causing enzyme EZH2 by attaching a phosphate group, preventing cancer cell migration and invasion. This process also plays a crucial role in bone formation.
A research team at Worcester Polytechnic Institute demonstrates the feasibility of delivering adult bone-marrow-derived stem cells using biopolymer microthreads, which support cell growth while maintaining differentiation potential. The technology has the potential to improve cardiac function and treat cardiac arrhythmias.
Researchers have developed a medical model for regenerating bladders using stem cells harvested from a patient's own bone marrow. The study demonstrates the feasibility of MSCs in partial bladder regeneration and provides valuable insight into the processes governing bladder regeneration.
Researchers at Harvard Medical School have found a way to rewind the internal clock of mature cells and drive them back into an adult stem-cell stage by mimicking a rare genetic disorder. This new approach has implications for personalized medicine, particularly in tissue engineering.
Researchers have developed a medical model for regenerating bladders using stem cells, which could lead to new organ replacement therapies. The study used bone marrow mesenchymal stem cells, which have been shown to retain their ability to populate and function in a grafted area.
A team of researchers has identified a key player in maintaining bone balance, finding that the protein Maf promotes bone formation and prevents osteoporosis. By understanding this age-related switch in cell type generation, new approaches to treat age-related osteoporosis may be developed.
A study by Dr. Paul Frenette reveals a unique 'partnership' between bone marrow stem cells, which could lead to advances in regenerative medicine. The partnership involves hematopoietic stem cells (HSCs) and mesenchymal stem cells, with the latter playing crucial roles in maintaining HSCs and facilitating regeneration.
Researchers successfully isolated bone marrow-derived MSCs that could differentiate into hepatocytes induced by VPA and well-defined cytokines. The study found that VPA-mediated facilitation of hepatic differentiation was regulated by FGF and HGF receptors, among other factors.
Researchers found that mesenchymal stem cells can triple survival rates in an experimental model of sepsis, a deadly condition caused by infection. The treatment also reduced inflammation and improved organ function in mice with severe sepsis.
Researchers have discovered a new source of stem cells that can form heart muscle cells, which can help repair damaged hearts. The stem cells, called human amniotic membrane-derived mesenchymal cells (hAMCs), were obtained from the amniotic membrane and showed promising results in laboratory studies.
Researchers from North Carolina State University found that very early calcium nutrition can impact long-term skeletal health. The study involved piglets fed a calcium-rich or deficient diet during infancy, resulting in marked differences in bone density and strength. This suggests that early nutritional programming may predispose indi...
Researchers have pinpointed a key molecular player to control mesenchymal stem cell development, which could lead to new therapies for bone and cartilage diseases. The study found that activating the Notch pathway can delay the development of these cells, potentially making them more useful for treating conditions like osteoporosis.
Researchers found that ALDH-positive tumor cells have a worse prognosis and are more likely to proliferate and invade compared to ALDH-negative cells. ALDH-positive cells were detected in 90% of primary surgical specimens and were associated with shorter overall survival.
Researchers at UT Houston are conducting a Phase II trial using adult human mesenchymal stem cells to treat acute heart attacks. The study shows promising results, with patients experiencing fewer arrhythmias and improved overall condition after receiving the treatment.
Researchers have found that transplanting human umbilical mesenchymal stem cells into mouse models can restore transparency to cloudy and thin corneas. The stem cells can survive in the stroma for over three months without rejection and become functional corneal cells.